Q-omics provides the consensus-scored TMCO5A profile across patient tissues and cancer cell-line models. TMCO5A expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, TMCO5A is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, TMCO5A RNA expression shows 5,806 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight THYM, STAD, and KIRC as cancer lineages where TMCO5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMCO5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMCO5A survival associations across molecular data types. TMCO5A RNA expression shows survival associations in the most cancer types (13), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMCO5A RNA expression–survival associations across cancer types. High TMCO5A expression shows unfavorable associations in THYM, UCS, PAAD, ESCA, READ and CHOL. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify THYM as the clearest survival context for TMCO5A RNA expression.
This table summarizes TMCO5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMCO5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMCO5A shows lower tumor expression in STAD and LUSC. The STAD box plot shows higher TMCO5A RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .001).
This table shows molecular features associated with TMCO5A in patient tissues and cancer cell lines. In patient samples, TMCO5A shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMCO5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
